Paratek Pharmaceuticals, Inc.

Informe acción NasdaqGM:PRTK

Capitalización de mercado: US$127.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Paratek Pharmaceuticals Dirección

Dirección controles de criterios 3/4

El CEO de Paratek Pharmaceuticals es Evan Loh , nombrado en Jun 2019, tiene una permanencia de 4.25 años. compensación anual total es $2.04M, compuesta por 31.8% salario y 68.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.87% de las acciones de la empresa, por valor de $2.38M. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 8.9 años, respectivamente.

Información clave

Evan Loh

Chief Executive Officer (CEO)

US$2.0m

Compensación total

Porcentaje del salario del CEO31.82%
Permanencia del CEO4.3yrs
Participación del CEO1.9%
Permanencia media de la dirección4.3yrs
Promedio de permanencia en la Junta Directiva8.9yrs

Actualizaciones recientes de la dirección

Recent updates

Artículo de análisis • Apr 17

Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) shares have had a really impressive month, gaining 77% after a shaky...
Seeking Alpha • Aug 24

Paratek Pharmaceuticals: Patience Is Wearing Thin

Summary Today, we put Paratek Pharmaceuticals in the spotlight for the first time since the early fall of last year. Paratek is advancing its flagship product NUZYRA nicely, but shareholders have not been rewarded to this point in time even as the shares have strong analyst support. What lies ahead for Paratek? An investment analysis follows in the paragraphs below. If you must speak ill of another, do not speak it, write it in the sand near the water's edge. ― Napoleon Hill Today, we are circling back on Paratek Pharmaceuticals (PRTK) for the first time since we posted this piece on this small antibiotic concern back in October of last year. Even as the company has demonstrated solid revenue growth, shareholders have not been rewarded in this name over the past year and patience is starting to wear thin. We update our investment thesis around Paratek Pharmaceuticals via the analysis below. Seeking Alpha Company Overview Paratek Pharmaceuticals is a Boston based antibiotic concern. The company's primary asset is NUZYRA. This is a once-daily oral and intravenous broad-spectrum antibiotic approved for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. The stock sells for around $2.75 a share and sports an approximate market cap of just under $150 million. August Company Presentation The company has some earlier stage candidates in its pipeline. None of them of note to this analysis given they are early in development. The company is advancing NUZYRA in Phase 2 development for Non-Tuberculous Mycobacteria or NTM for which it has Orphan Drug and Fast Track designations from the FDA. August Company Presentation Second Quarter Results On August 3rd, the company posted second quarter numbers. Paratek posted a GAAP loss of 33 cents a share, just a tad above the consensus. Net revenue for the second quarter of 2022 was $29.6 million. This compares to $19.6 million in 2Q2021 when excluding the first procurement of NUZYRA under the BARDA contract of $37.9 million (more detail on that contract in the last section of this article). August Company Presentation The $29.6 million in sales for the quarter included $25.1 million of revenues from NUZYRA's core commercial business. This was up from $14.9 million from the same period a year ago. The company also booked $4 million in sales from the BARDA contract and $600,000 in royalty revenue from SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. August Company Presentation Analyst Commentary & Balance Sheet Only three analyst firms have chimed in around Paratek so far in 2022. On February 10th, WBB Securities upgraded the shares to a Strong Buy with a $11 price target as the analyst there believes 'Nuzyra is a critically important antibiotic that has anchored the franchise'. This month BTIG ($30 price target) and H.C. Wainwright ($20 price target) both maintained their Buy ratings on the stock. Just under 10% of the outstanding float is currently held short. Four insiders sold just over $300,000 worth of shares collectively in August. That has been the only insider activity in the equity so far in 2022. The company ended the first half of this year with nearly $70 million in cash and marketable securities on its balance sheet. Management stated within its second quarter earnings press release that: Based upon the company's current operating plan, Paratek anticipates its existing cash, cash equivalents and marketable securities of $69.4 million as of June 30, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even. August Company Presentation Verdict The current analyst consensus has the company losing a bit over 80 cents a share in FY2022 as revenues rise in the mid teens to some $150 million. Projections from three analyst firms that have provided estimates for FY2023 are in wide range both for earnings (A 42 cent a share loss to profits of $1.37 a share) and revenues ($195 million to $315 million).
Seeking Alpha • Aug 03

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Paratek Pharmaceuticals press release (NASDAQ:PRTK): Q2 GAAP EPS of -$0.33 beats by $0.01. Revenue of $29.6M (-48.5% Y/Y) beats by $0.42M. Based upon the company’s current operating plan, Paratek anticipates its existing cash, cash equivalents and marketable securities of $69.4M as of June 30, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even.
Seeking Alpha • Jan 03

Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company

2021 revenue estimate: $128-139 million; 2022 revenue estimate: $200 million. Revenue estimates for CABP and ABSSSI near $400 million by 2028; NTM could generate even higher sales well into the 2030s. $304 million BARDA contract (2019-2023) provides a pathway to profitability by 4Q2022. Deeply undervalued: enterprise value of $369 million is less than 2X 2022 sales.
Seeking Alpha • Oct 18

The Play On Paratek Pharmaceuticals

Today, we take a quick look back at antibiotic concern Paratek Pharmaceuticals. While I am very underweight the antibiotic space due to the terrible economics there, Paratek has some unique features that make the stock one I own. An analysis and how I am positioned in Paratek Pharmaceuticals follows in the paragraphs below.
Seeking Alpha • Aug 07

Peeking Back In On Paratek Pharmaceuticals

The stock of Paratek Pharmaceuticals has fallen since we last took an in-depth look at this antibiotic company in March. Most of this is due to weakness in the sector. The company continues to make solid progress, and its shares are far below analyst firm price targets. A full and independent investment analysis follows in the paragraphs below.
Artículo de análisis • Mar 01

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) is possibly approaching a major achievement in its business, so we would...
Artículo de análisis • Feb 01

Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

A look at the shareholders of Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) can tell us which group is most powerful...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Evan Loh en comparación con los beneficios de Paratek Pharmaceuticals?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2023n/an/a

-US$63m

Mar 31 2023n/an/a

-US$66m

Dec 31 2022US$2mUS$650k

-US$64m

Sep 30 2022n/an/a

-US$89m

Jun 30 2022n/an/a

-US$86m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$4mUS$600k

-US$59m

Sep 30 2021n/an/a

-US$52m

Jun 30 2021n/an/a

-US$54m

Mar 31 2021n/an/a

-US$87m

Dec 31 2020US$2mUS$575k

-US$97m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$111m

Mar 31 2020n/an/a

-US$121m

Dec 31 2019US$2mUS$520k

-US$129m

Sep 30 2019n/an/a

-US$124m

Jun 30 2019n/an/a

-US$124m

Mar 31 2019n/an/a

-US$120m

Dec 31 2018US$2mUS$480k

-US$112m

Sep 30 2018n/an/a

-US$111m

Jun 30 2018n/an/a

-US$101m

Mar 31 2018n/an/a

-US$89m

Dec 31 2017US$3mUS$450k

-US$89m

Sep 30 2017n/an/a

-US$94m

Jun 30 2017n/an/a

-US$96m

Mar 31 2017n/an/a

-US$108m

Dec 31 2016US$1mUS$415k

-US$112m

Compensación vs. Mercado: La compensación total de Evan($USD2.04M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD627.03K).

Compensación vs. Ingresos: La compensación de Evan ha sido consistente con los resultados de la empresa en el último año.

CEO

Evan Loh (64 yo)

4.3yrs
Permanencia
US$2,042,511
Compensación

Dr. Evan Loh, M.D., FACC, FAHA, has been the Chief Executive Officer of Paratek Pharmaceuticals, Inc. since June 25, 2019. Dr. Loh served as Independent Director at Windtree Therapeutics, Inc. since Februa...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Michael Bigham
Executive Chairman8.9yrsUS$1.73m1.93%
$ 2.5m
Evan Loh
CEO & Director4.3yrsUS$2.04m1.87%
$ 2.4m
Adam Woodrow
President & Chief Commercial Officer4.3yrsUS$1.15m1.09%
$ 1.4m
Sarah Higgins
VP of Finance8.5yrssin datossin datos
William Haskel
Senior VP8.3yrsUS$1.25m0.62%
$ 797.8k
Jonathan Light
Deputy General Counsel & Chief Compliance Officer6.1yrssin datossin datos
Karen McGrath
Chief People Officer4.2yrssin datossin datos
Randall Brenner
Chief Development & Regulatory Officer4.3yrssin datos0.58%
$ 735.2k
4.3yrs
Permanencia media
58.5yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de PRTK se considera experimentado (4.3 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Michael Bigham
Executive Chairman8.9yrsUS$1.73m1.93%
$ 2.5m
Evan Loh
CEO & Director11.3yrsUS$2.04m1.87%
$ 2.4m
Jeffrey Stein
Lead Independent Director8.9yrsUS$147.80k0.097%
$ 124.0k
Thomas Dietz
Independent Outside Director8.9yrsUS$150.30k0.087%
$ 111.5k
Kristine Peterson
Independent Outside Director7.5yrsUS$137.80k0.10%
$ 131.6k
Timothy Franson
Independent Outside Director8.2yrsUS$135.30k0.10%
$ 131.6k
Robert Radie
Independent Outside Director8.9yrsUS$140.30k0.091%
$ 116.5k
Rolf Hoffmann
Independent Director5.4yrsUS$127.80k0.11%
$ 142.7k
Minnie Baylor-Henry
Independent Director2.3yrsUS$132.80k0.068%
$ 87.4k
8.9yrs
Permanencia media
64yo
Promedio de edad

Junta con experiencia: La junta directiva de PRTK se considera experimentada (8.9 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2023/09/22 21:47
Precio de las acciones al final del día2023/09/20 00:00
Beneficios2023/06/30
Ingresos anuales2022/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Paratek Pharmaceuticals, Inc. está cubierta por 11 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Michael UlzBaird
Jason Matthew GerberryBofA Global Research
Timothy ChiangBTIG